Ligand price target raised to $151 from $135 at Oppenheimer

TipRanks12-12

Oppenheimer raised the firm’s price target on Ligand (LGND) to $151 from $135 and keeps an Outperform rating on the shares following the company’s investor day. Key takeaways, the firm says, include ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490389259?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lBatGXdmW601L3jZUeEVwQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/e1839507ce9d5542b9a5313ac8d70b9e","is_english":true,"pubTime":"2024-12-12 20:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490389259","market":"us","top_or_hot":-1,"title":"Ligand price target raised to $151 from $135 at Oppenheimer","media":"TipRanks","content":"<div>\n<p>Oppenheimer raised the firm’s price target on Ligand (LGND) to $151 from $135 and keeps an Outperform rating on the shares following the company’s investor day. Key takeaways, the firm says, include ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ligand-price-target-raised-151-124551901.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ligand price target raised to $151 from $135 at Oppenheimer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLigand price target raised to $151 from $135 at Oppenheimer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ligand-price-target-raised-151-124551901.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oppenheimer raised the firm’s price target on Ligand (LGND) to $151 from $135 and keeps an Outperform rating on the shares following the company’s investor day. Key takeaways, the firm says, include ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ligand-price-target-raised-151-124551901.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPY","symbol_name":"奥本海默控股","start_time":0,"source_url":"https://finance.yahoo.com/news/ligand-price-target-raised-151-124551901.html","article_id":"2490389259","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lBatGXdmW601L3jZUeEVwQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/e1839507ce9d5542b9a5313ac8d70b9e"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ligand-price-target-raised-151-124551901.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2490389259","pubTimestamp":1734007551,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Oppenheimer raised the firm’s price target on Ligand  to $151 from $135 and keeps an Outperform rating on the shares following the company’s investor day. Key takeaways, the firm says, include capital needs within biotech/biopharma remain massive; investments will continue to be selective, and lean on their expertise; Zelsuvmi opportunity remains underappreciated; further levers of potential value creation exist with an emphasis on Captisol sales growth; and Captisol/Nitricil platform value.Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. Ligand backs FY24 adjusted EPS view $5.50-$5.70, consensus $5.65. Ligand price target raised to $141 from $140 at RBC Capital","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"OPY":"奥本海默控股","LGND":"Ligand Pharmaceuticals Inc."},"translate_title":"奥本海默配体目标价格从135美元上调至151美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPY":1,"LGND":0.9},"content_text":"Oppenheimer raised the firm’s price target on Ligand (LGND) to $151 from $135 and keeps an Outperform rating on the shares following the company’s investor day. Key takeaways, the firm says, include capital needs within biotech/biopharma remain massive; investments will continue to be selective, and lean on their expertise; Zelsuvmi opportunity remains underappreciated; further levers of potential value creation exist with an emphasis on Captisol sales growth; and Captisol/Nitricil platform value.\n\nPick the best stocks and maximize your portfolio:\n\nDiscover top-rated stocks from highly ranked analysts with Analyst Top Stocks!\nEasily identify outperforming stocks and invest smarter with Top Smart Score Stocks\n\n\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee today’s best-performing stocks on TipRanks >>\n\n\nRead More on LGND:\n\nLigand provides updated five-year outlook\nLigand backs FY24 adjusted EPS view $5.50-$5.70, consensus $5.65\nLigand sees FY25 EPS $6.00-$6.25, consensus $6.03\nLigand to hold investor and analyst day\nLigand price target raised to $141 from $140 at RBC Capital","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490389259"}